Abstract
Neurosarcoidosis is an uncommon but potentially serious manifestation of sarcoidosis. While the cranial nerves are most frequently affected, neurosarcoidosis can involve other nervous system tissues including the meninges, brain parenchyma (especially the hypothalamic region), spinal cord, peripheral nerve, and muscle. Diagnosis may be particularly challenging when neurosarcoidosis occurs in isolation. Diagnostic criteria usually include histologic identification of a noncaseating granuloma, supportive laboratory or imaging tests or both, and a compatible clinical course. Treatment has not been subjected to rigorous study, but corticosteroids are typically the first line of therapy and approximately half of patients have substantial benefit. For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and even cranial irradiation. The combination of infliximab and mycophenolate mofetil is under study as well. Treatment options will likely evolve as well-designed studies are undertaken.
Keywords: Neurosarcoidosis, sarcoidosis, cranial neuropathy, meningitis, neuroendocrine dysfunction, seizures, peripheral neuropathy, myopathy
Current Neuropharmacology
Title: Neurosarcoidosis
Volume: 9 Issue: 3
Author(s): David Lacomis
Affiliation:
Keywords: Neurosarcoidosis, sarcoidosis, cranial neuropathy, meningitis, neuroendocrine dysfunction, seizures, peripheral neuropathy, myopathy
Abstract: Neurosarcoidosis is an uncommon but potentially serious manifestation of sarcoidosis. While the cranial nerves are most frequently affected, neurosarcoidosis can involve other nervous system tissues including the meninges, brain parenchyma (especially the hypothalamic region), spinal cord, peripheral nerve, and muscle. Diagnosis may be particularly challenging when neurosarcoidosis occurs in isolation. Diagnostic criteria usually include histologic identification of a noncaseating granuloma, supportive laboratory or imaging tests or both, and a compatible clinical course. Treatment has not been subjected to rigorous study, but corticosteroids are typically the first line of therapy and approximately half of patients have substantial benefit. For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and even cranial irradiation. The combination of infliximab and mycophenolate mofetil is under study as well. Treatment options will likely evolve as well-designed studies are undertaken.
Export Options
About this article
Cite this article as:
Lacomis David, Neurosarcoidosis, Current Neuropharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157015911796557975
DOI https://dx.doi.org/10.2174/157015911796557975 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Age-Dependent Microglial Activation in Immature Brains After Hypoxia- Ischemia
CNS & Neurological Disorders - Drug Targets Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Feline Immunodeficiency Virus Model for Designing HIV/AIDS Vaccines
Current HIV Research New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ To ‘Ditans’
Current Clinical Pharmacology Update on the Development of TB Vaccines
Current Pharmaceutical Biotechnology State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens
Anti-Infective Agents in Medicinal Chemistry Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology New Agents to Treat Life-Threatening Fungal Infections
Current Topics in Medicinal Chemistry Immunotoxins and Neuropeptide-Toxin Conjugates Experimental Applications
Mini-Reviews in Medicinal Chemistry Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Molecular and Cellular Mechanisms in the Pathophysiology of Severe Head Injury
Current Pharmaceutical Design L-Carnosine Modulates Respiratory Burst and Reactive Oxygen Species Production in Neutrophil Biochemistry and Function: May Oral Dosage Form of Non-Hydrolized Dipeptide L-Carnosine Complement Anti-Infective Anti-Influenza Flu Treatment, Prevention and Self-Care as an Alternative to the Conventional Vaccination?
Current Clinical Pharmacology Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Neural Stem Cell Plasticity: Recruitment of Endogenous Populations for Regeneration
Current Neurovascular Research Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design Rethinking the Excitotoxic Ionic Milieu:The Emerging Role of Zn 2+ in Ischemic Neuronal Injury
Current Molecular Medicine Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry